Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-I&T in advanced salivary gland cancer
NCT04291300Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2020
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 PSMA I&T in salivary gland cancer (SGC), adenoid cystic carcinoma (ACC), salivary duct carcinoma (SDC), sponsored by Radboud University Medical Center. Started May 2020; status: completed.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
salivary gland cancer (SGC)adenoid cystic carcinoma (ACC)salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on NCT04291300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04291300.